• Home
  • Search Results

Search Results

Young Adult (18-34)
2339 studies match your search
Coming Soon

Analysis of Treatment Patterns in Long-term Survivors of Pancreatic Cancer

Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Visit Location
100% Remote (online, phone, text)
Open

GD2-CAR-T cell therapy for small cell and non-small cell lung cancers

Do you have small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)? Has your lung cancer come back or did not get better with the last treatment you were given? If so, you may be able to take part in a gene therapy research study that uses your own modified immune cells as treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung, Phase 1 Trials (all cancers))

An Acute Leukemia Study

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)

Characterization of Circulating Tumor DNA Kinetics During Radiation Therapy, Treatment Monitoring, and Surveillance: A Pilot Study in Hematologic and Pediatric Malignancies

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Age & Gender
  • 2 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Pediatric Cancers, Lymphoma)

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Other Cancers, Ovarian)
Open

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Dupilumab for Eosinophilic Esophagitis with Severe Strictures (DESTRICT Study)

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

Age & Gender
  • 16 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Ear, Nose, and Throat
Open

Study of sacituzumab govitecan with or without pembrolizumab in Metastatic TNBC

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Not currently enrolling

Physical Activity in College-Age Native American Adults

The purpose of this study is to assess the physical activity practices of college-age Native American adults.

Age & Gender
  • 18 years ~ 25 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)

Radiation, PARP inhibition, and immunotherapy for breast cancer brain metastasis

The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Cancer (Brain and Other Nervous System, Breast)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research